The emergence of SARS-CoV-2 lineages and associated antibody responses among asymptomatic individuals in a large university community

I. Study overview

The first confirmed cases of COVID in the state of Ohio were reported on Mar 9 2020 (50). The Ohio State University suspended on campus activities the same day (51) and subsequently developed a campus wide plan to monitor the incidence of CoV2 infection among its students, staff and faculty (52). Individuals participating in this monitoring program, which formally began in Aug 2020, provided saliva on a weekly basis for COVID testing. Prior to testing, individuals who self-reported as being symptomatic were not tested and were instead given a clinical referral (see Methods for additional details). Individuals who self-reported as being asymptomatic provided a saliva specimen via a passive drool method at each of our six university campuses (FIG 1A). Specimens were assessed by our CLIA-certified lab for the presence of CoV2 using real-time quantitative reverse transcription PCR (qRT-PCR). Specimens were not pooled prior to testing. qRT-PCR results were reported to the individual and the regional public health authority per state and federal policies at the time. If a specimen had a C_T value ≤ 40 it was considered positive for CoV2 virus (PCR^POS). Per our Institutional Review Board (IRB) approved protocols and workflows (FIG 1B), PCR^POS saliva samples were subsequently used for CoV2 lineage identification and CoV2-specific immunoglobulin (CoV2-Ig) measurements. In some instances, select saliva samples that were negative for CoV2 virus (PCR^NEG) were also collected, the reasons for which will be made clear in sections below. The relationships between these molecular and immunological readouts to one another, as well as to coded data concerning the prior infection status and vaccination status of the saliva donor, are described below for the period spanning Jan 2021 (before COVID vaccines were widely available to students in our university community) to June 2022, when the monitoring program ended. See Methods for details regarding saliva collection, symptomatic versus asymptomatic designation, qRT-PCR, CoV2 lineage identification, CoV2-Ig measurements, and statistical analyses. In total, >850,000 diagnostic PCR tests were performed by our lab during this monitoring program.

II. The incidence of CoV2 positivity in our university community occurred in waves which reflected those occurring in surrounding regions

The incidence of new PCR^POS cases among asymptomatic individuals in our university community, for the period spanning Jan 2021→June 2022, is shown in FIG 2. COVID monitoring occurred before Jan 2021; however, because the bulk of PCR testing at that time was contracted to a commercial entity, our access to the raw PCR data before Jan 2021 is limited. Above these data are two timelines relevant to data interpretation, indicating when Ohio COVID vaccination policies shifted from prioritizing at risk populations (e.g. elderly) to anyone ≥16 years of ages well as the deadlines for all our community members (i.e. university students, faculty and staff) to have received their first and second COVID doses (Oct 15 2021 and Nov 15 2021, respectively) (53). Indicated below the data are corresponding intervals in the academic calendar, which will be referred to in subsequent sections. We identified 11,989 PCR^POS individuals between Jan 2021→June 2022; the median, mean and maximum new PCR^POS cases per test day were 15, 34 and 523, respectively. There were, however, six time periods when the new case counts rose above the overall period median for ≥ 3 weeks in a row. These six time periods are hereafter referred to as Waves 1–6 and spanned the following dates: Wave 1, Jan 11 2021→ Jan 29 2021; Wave 2, Feb 22 2021→ Mar 12 2021; Wave 3, Mar 22 2021→ Apr 16 2021; Wave 4, Aug 16 2021→ Sep 24 2021; Wave 5, Nov 15 2021→ Feb 18 2022; Wave 6, Apr 18 2022→ May 6 2022. The waves of COVID incidence amongst asymptomatic individuals in our university community mirrored (rather than preceded) the waves of COVID incidence in the counties surrounding each university campus (54) (supplemental FIG S2).

• Download figure
• Open in new tab

FIGURE 2. The incidence of PCR positivity among asymptomatic members of our university community.

Saliva samples from asymptomatic individuals were collected on a daily basis and tested by qRT-PCR for the presence of the CoV2 N gene. Shown are the number of PCR^POS saliva samples identified each day during the period spanning Jan 2021 → May 2022, with each bar representing a single day. Above the graph is a timeline depicting when COVID vaccine availability shifted in Ohio (i.e. when the national vaccination priority expanded from vulnerable populations to encompass anyone >15 years of age), as well as indications of the deadlines by which all university community members were required to have received their first and second vaccine dose of either the BNT162b2 or mRNA-1273 vaccines. Below the graph are indications of the periods we refer to as Waves 1-6, a wave being defined as when the daily PCR^POS case count exceeded the period median (15) for ≥3 weeks, as well Blue shading indicates when the samples we used for CoV2 Ig measurements were collected.

III. Prior to community vaccine requirements being established, CoV2 was becoming progressively more concentrated in the saliva of asymptomatic individuals

The emergence of CoV2 lineage variants in multiple Ohio communities (55-61) with potential for greater infectivity and/or transmissibility led us to assess the relationship between CoV2 abundance in saliva and variant identity. We used the qRT-PCR cycle threshold (C_T) value as a readout of CoV2 abundance, as the SalivaDirect C_T value is inversely proportional to CoV2 viral load (i.e. a lower C_T value corresponds to higher CoV2 RNA levels in the tested sample) (45), and a commonly used as a proxy for probability of transmission (i.e. a lower C_T value correspond to higher transmission probability) (62-66). Variant identity was determined by next generation sequencing of the entire CoV2 genome and subsequent alignment with Global Initiative on Sharing Avian Influenza Data (GISAID) reference sequences. During the entire monitoring period, CoV2 genome sequences were submitted to the GISAID database in a manner consistent with ODH expectations and policies at that time, in as close to real time as possible.

The weekly composite and daily individual C_T values of each PCR^POS individual over this period are shown in FIG 3A and FIG 3B, respectively, with color annotations in FIG 3B indicating the lineage identity. The same data are presented in two ways (weekly composite versus daily individual) in order to best illustrate the following trends: During Wave 1 (Week 2 of Jan 2021 → Week 4 of Jan 2021), the median weekly C_T values of all PCR^POS saliva samples ranged between 29 - 30.5 (FIG 3A). During Wave 2 (Week 4 of Feb 2021 → Week 2 of Mar 2021) the median weekly C_T values ranged between 28 - 30.5 (FIG 3A). The median C_T range lowered and tightened during Wave 3 (Week 4 of Mar 2021 → Week 2 of Apr 2021) median weekly C_T values ranged from 28.5 - 29.5 (FIG 3A). The number of tests performed fell precipitously during Jun 2021 and Jul 2021, as the campus population is minimal during the summer months; therefore, we are reluctant to draw conclusions from or otherwise compare Summer 2021 C_T value data to the prior semester, when testing volume was higher. Upon resumption of high-volume testing during the later weeks of August 2021, which marked the beginning of the Autumn 2021 semester and Wave 4 (Week 3 of Aug 2021 → Week 3 of Sept 2021), we noted the lowest median C_T range of all waves (27.0 - 27.5) (FIG 3A). The cumulative C_T data during each wave (FIG 3C) and extrapolated CoV2 genome copy concentrations (FIG 3D) are consistent with Wave 4 saliva samples having the highest virus concentrations of all waves. Wave 5 was the longest wave (Week 3 of Nov 2021 → Week 2 of Feb 2022) with daily PCR^POS cases reaching a maximum of 523 on Jan 11, 2022. The C_T value range during Wave 5, which followed our community deadline for vaccine requirements, was significantly higher than that of Wave 4 (FIG 3B). The last wave before the COVID monitoring program ended, Wave 6 (Week 2 of Apr 2022 → Week 1 of May 2022), had lower C_T values than Wave 5 (FIG 3B). The lowest C_T value we ever observed was on Feb 18 2021 (C_T=14.2).

• Download figure
• Open in new tab

FIGURE 3. Saliva CoV2 viral loads among asymptomatic members of our university community.

(A) Box plot representation of all the C_T values of all the PCR^POS saliva samples during each week of the period spanning Jan 2021 → Jun 2022. The blue line passes through the median C_T value of each week. Below the graph are indications of the periods corresponding to Waves 1-6 of the prior figure. (B) Scatter plot representation of the same C_T value data as in (A) above, the exceptions being daily data are shown (as opposed to weekly composites) and samples with a C_T >33 are omitted (these could not be sequenced due to insufficient amounts of genetic material). Each dot represents an individual sample; the color of each diamond indicates the CoV2 lineage present (Green, CoV2^US; Pink, CoV2^Alpha; White, CoV2^Beta ; Blue, CoV2^Gamma; Red, CoV2^Delta; Gold, CoV2^O-BA.1; Orange, CoV2^O-BA.2). Gray diamonds indicate samples whose lineage was not a VOC. Black squares indicate a sequence that did not align to known lineages and thus could not be assigned. Note that CoV2^Beta only appeared once in our university community, on Apr 15 2021. (C) The C_T value and (D) calculated CoV2 genome copy concentration in of each positive sample during Wave 1, Wave 2, Wave 3, Wave 4, Wave 5 and Wave 6. The “Vax” arrow indicates when community vaccine requirements went into effect (after Wave 4, before Wave 5). Asterisks indicate those inter-wave differences that were statistically significant, as determined by one way ANOVA (* p≤ 0.05, ** p≤ 0.005, *** p≤ 0.0005, *** p≤ 0.00005).

IV. Each wave of CoV2 positivity corresponded to the emergence of a new CoV2 lineage within our community

The CoV2 lineages present in each individual PCR^POS sample during the same time periods as above are shown in FIG 3B, exceptions being samples with a C_T value of >33 as these could not be sequenced due to the viral RNA levels being too low. Among sequenced samples, the median and mean ages of infected individuals were 21 and 23, respectively, and varied minimally during the monitoring period (supplemental FIG S3). Males were more likely to meet sequencing criteria (i.e. a C_T ≤ 33) than females during Waves 1-3 (supplemental FIG S4); this was not true of later Waves, however, and female representation was higher during the entire monitoring period overall (supplemental FIG S4). During the period spanning Jan 2021 to mid-Feb 2021, the predominant lineage was B.1.2, which we hereafter refer to as CoV2^US since it was among the first detected in our region of the United States (46-48). The period of CoV2^US lineage predominance corresponds to Wave 1 in our community (FIG 2, FIG 3B). Beginning mid-Feb 2021 and extending to mid-Mar 2021 was a period of time when an array of lineages which we collectively refer to as “non-VOC” were predominant, as they were more diverse compared to earlier and later testing periods and were never considered to be Variants of Concern (VOC). Although the CoV2^US lineage was still being detected, Wave 2 primarily comprised of non-VOCs (FIG 3B). As the Ides of March approached in 2021, so too did two VOCs begin appearing with increasing frequency: the Alpha VOC (CoV2^Alpha) and Gamma VOCs (CoV2^Gamma). CoV2^Alpha and CoV2^Gamma were widely considered at that time to be more transmissible than previous lineages (9, 67). CoV2^Alpha and CoV2^Gamma were the primary lineages detected during Wave 3 (FIG 3B), and continued to predominate among the few positive samples collected during May 2021. The Beta VOC (CoV2^Beta) only appeared once in our university community (Apr 15, 2021). Beginning Jun 2021 and continuing through Dec 2021 the new Delta VOC (CoV2^Delta) made up the vast majority of PCR^POS saliva samples (FIG 3B). CoV2^Delta is more transmissible than CoV2^Alpha and CoV2^Gamma (68), and the period in which CoV2^Delta predominated coincided with COVID Wave 4 in our community (FIG 2). Wave 5, the penultimate and largest COVID wave, coincided with the emergence and dominance of the Omicron VOC (CoV2^Omicron) subvariant, BA.1 (CoV2^O-BA.1). Wave 6, final wave before our COVID monitoring program ended, was dominated by the CoV2^Omicron subvariant BA.2 (CoV2^O-BA.2) (FIG 3B). When considered alongside the C_T values and CoV2 genome copy numbers that characterized each wave (FIG 3C-D), the above data demonstrate that the shift from CoV2^US → CoV2^Alpha/CoV2^Gamma → CoV2^Delta coincided with the virus becoming progressively more concentrated in the saliva of asymptomatic individuals, this trend ending after community vaccine requirements were established.

V. Among pre-Omicron lineages, CoV2^Delta elicited the highest levels of Spike-specific IgA and IgG in unvaccinated, asymptomatic individuals

In symptomatic CoV2 PCR^POS individuals, CoV2-specific Ig levels in the circulation and airways increase at variable rates depending on the isotype (22). To assess whether CoV2-specific Ig was detectable in the saliva of asymptomatic CoV2 PCR^POS individuals, as well as whether levels of the same Ig varied depending on the CoV2 lineage present, we used the same samples described above (i.e. those used for lineage identification) to measure saliva levels of CoV2 Spike-specific IgM (IgM^Spike), CoV2 Spike-specific IgA (IgA^Spike) and CoV2 Spike-specific IgG (IgG^Spike) (FIG 4). Individuals vaccinated against COVID were excluded from this analysis (the vaccination record of each person in our university community was closely monitored during this time period), and saliva samples from individuals infected with CoV2^Anc, CoV2^Alpha and CoV2^Gamma were collected prior to COVID vaccines being widely available in our community; therefore, no vaccine-elicited antibody responses would be expected in these samples. Among individuals infected with CoV2^Delta, only unvaccinated individuals were included in the FIG 4 analysis. To eliminate viral load as a confounding variable, only PCR^POS saliva samples with similar C_T range were used for Ig comparisons (C_T range = 22-26). PCR^NEG saliva collected in early 2020 from healthy individuals living in the US and no COVID history were used to estimate “pre-pandemic” levels of IgM^Spike, IgA^Spike of IgG^Spike binding.

• Download figure
• Open in new tab

FIGURE 4. Spike-specific Ig levels in the saliva of newly positive, asymptomatic individuals at the time of PCR testing.

Saliva samples from individuals who were newly positive (New^POS, PCR positive for the first time ever) for either the CoV2^US, CoV2^Alpha, CoV2^Gamma or CoV2^Delta lineage were used to measure the concentrations of (A) IgM^Spike, (B) IgA^Spike and (C) IgG^Spike. The CoV2^Anc Spike was used as the capture antigen in each case, and concentrations are expressed as World Health Organization (WHO) binding antibody units (BAU) per mL. PCR^NEG saliva collected in early 2020, from healthy individuals living in the US with no COVID history, was tested in the same manner used to estimate “pre-pandemic” levels of IgM^Spike, IgA^Spike and IgG^Spike binding, which are represented by the dashed lines on each graph. ^X, values that were considered outliers but are nevertheless shown for completeness and are included in all statistical group comparisons. * p≤ 0.05, as determined by unpaired Wilcoxon tests with Benjamini-Hochberg adjustment.

Saliva IgM^Spike (FIG 4A), IgA^Spike (FIG 4B) and IgG^Spike (FIG 4C) data are shown relative to which CoV2 lineage was detected in the same saliva donor (CoV2^US, CoV2^Alpha, CoV2^Gamma or CoV2^Delta) and are expressed as WHO binding antibody units, or BAUs. As shown in FIG 4A-C, respectively, nearly all PCR^POS individuals had saliva IgM^Spike, IgA^Spike and IgG^Spike levels that were above “pre-pandemic” levels, regardless of whether they were infected with CoV2^US, CoV2^Alpha, CoV2^Gamma or CoV2^Delta. There were, however, three noteworthy differences between PCR^POS individuals depending on the lineage present. First, whereas individuals infected with CoV2^US and CoV2^Alpha had similar IgM^Spike levels, those infected with CoV2^Gamma and CoV2^Delta had higher IgM^Spike levels relative to those infected with CoV2^US (FIG 4A). Second, saliva IgA^Spike levels were similar between individuals infected with CoV2^US, CoV2^Alpha and CoV2^Gamma; CoV2^Delta infected individuals, on the other hand, had significantly higher IgA^Spike levels compared to those infected with CoV2^US, CoV2^Alpha or CoV2^Gamma (FIG 4B). Third, saliva IgG^Spike levels were elevated in CoV2^Alpha-infected individuals relative to CoV2^US-infected individuals (FIG 4C); however and analogous to IgA^Spike differences (FIG 4B), CoV2^Delta-infected individuals had significantly higher IgG^Spike levels compared to those infected with CoV2^US, CoV2^Alpha or CoV2^Gamma (FIG 4C). For IgM^Spike, IgA^Spike and IgG^Spike measurements, the recombinant Spike antigen used for Ig detection was identical to that of CoV2^Anc, as this enabled data transformation to WHO BAU (see Methods); the same patterns were observed, however, when the same saliva samples were tested against recombinant CoV2^Alpha, CoV2^Beta, and CoV2^Gamma Spike antigens (Supplemental FIG S5).

VI. Following infection of unvaccinated individuals, IgG^Spike and IgG^RBD persisted at higher levels in saliva than IgG^N

To determine the extent to which CoV2-specific IgG in saliva was sustained over time, we performed the analysis shown in FIG 5 wherein saliva IgG^Spike levels, as well as Nucleocapsid (N)-specific IgG (IgG^N) levels, were compared across two groups of individuals: “New^POS” individuals who, at the time of saliva collection, were positive for either CoV2^US or CoV2^Alpha; “Prior^POS” individuals who were uninfected at the time of saliva collection, but had been PCR^POS 3-9 months earlier. In this instance, saliva samples from Prior^POS individuals were collected in May 2021. Most individuals in our Prior^POS cohort were infected during the Autumn 2020 semester, before COVID vaccines were available; therefore, any saliva IgG^Spike or IgG^N present would have formed after natural infection (not vaccination). As in the previous figure, individuals with a record of COVID vaccination were excluded from this analysis.

• Download figure
• Open in new tab

FIGURE 5. Nucleocapsid- and Spike-specific IgG levels in saliva of newly positive, asymptomatic individuals versus prior positive, asymptomatic individuals.

Saliva from New^POS individuals infected with either CoV2^US or CoV2^Alpha, as well as PCR^NEG saliva from individuals who had been infected 3-9 months prior (Prior^POS) with either CoV2^US, CoV2^Alpha or a non-VOC, were used to measure the concentrations of (A) Nucleocapsid-specific IgG, (B) Spike-specific IgG, and (C) Spike RBD-specific IgG. * p≤ 0.05, as determined by unpaired Wilcoxon test with Benjamini-Hochberg adjustment.

Among New^POS individuals, saliva IgG^N levels were similar regardless of whether they were infected with CoV2^US or CoV2^Alpha (FIG 5A), as were saliva IgG^Spike levels (FIG 5B; note the data points in the first two columns of FIG 5B are the same as those in the first two columns of FIG 4C). Relative to New^POS individuals, saliva IgG^N levels in Prior^POS individuals were higher (FIG 5A); however, the difference in saliva IgG^Spike levels between New^POS versus Prior^POS individuals was more pronounced (FIG 5B). Saliva IgG^Spike levels were highest in Prior^POS individuals (FIG 5B) and reacted against the Spike RBD domain (FIG 5C). These results indicate that although IgG^N and IgG^Spike both persist in saliva following natural infection, IgG^Spike persists at higher levels and reacts against Spike regions that are essential for ACE2 binding (i.e., the RBD).

VII. Individuals with breakthrough CoV^Delta infections had comparable saliva IgG^Spike levels to those of uninfected, vaccinated individuals

During the period of Dec 2020 – Mar 2021, COVID vaccination was prioritized and available to the elderly and other individuals at increased risk of severe disease (e.g. healthcare workers, first responders). In Ohio, beginning on Mar 22 2021, individuals who were 16 years or older could receive a COVID vaccine, including all college students (69). Despite the widespread availability of vaccines by our Autumn 2021 semester, CoV2^Delta lineage infections occurred among unvaccinated (Vax^NEG) individuals and vaccinated (Vax^POS) individuals. The term “breakthrough infection” is older than COVID (70) but is now commonly applied to individuals who are PCR^POS despite their being Vax^POS. Since BNT162b2, mRNA-1273 and Ad26.COV2.S were each designed to elicit an Ig response against CoV2 Spike (since it is essential for CoV2 infection of ACE2-expressing cells), we assessed whether breakthrough infections with CoV2^Delta were associated with lower levels of Spike-specific Ig in saliva compared to PCR (neg) vaccinates. Shown in FIG 6 are saliva levels of IgM^Spike, IgA^Spike and IgG^Spike in three groups of individuals: VAX^NEGPCR^POS individuals infected with CoV2^Delta, VAX^POSPCR^POS individuals infected with CoV2^Delta, and VAX^POSPCR^NEG individuals. Saliva from VAX^NEGPCR^POS and VAX^POSPCR^POS individuals was collected during Wave 4 (FIG 2), when community viral burdens were their highest (FIG 3D); saliva from VAX^POSPCR^NEG individuals was collected shortly after Wave 4 had passed. These results demonstrate that VAX^POSPCR^POS and VAX^POSPCR^NEG groups each had significantly higher saliva IgG^Spike levels than VAX^NEGPCR^POS individuals (FIG 6C). Furthermore, the saliva IgG^Spike levels of VAX^POSPCR^POS and VAX^POSPCR^NEG groups did not significantly differ from one another (FIG 6C). Notably, although saliva IgM^Spike levels were indistinguishable across groups (FIG 6A), VAX^NEGPCR^POS individuals were distinguished by the highest levels of saliva IgA^Spike (FIG 6B). Similar trends were observed using recombinant CoV2^Alpha, CoV2^Beta, CoV2^Gamma and CoV2^Delta Spike as capture antigens (Supplemental FIG S6). We conclude from this that COVID vaccination increased saliva IgG^Spike levels in our university community as intended, the saliva IgG^Spike levels in all vaccinees being comparable (regardless of whether they had a breakthrough CoV^Delta infection) and significantly higher than the saliva IgG^Spike levels of unvaccinated, infected individuals.

• Download figure
• Open in new tab

FIGURE 6. Spike-specific Ig levels in saliva of CoV2^Delta-infected unvaccinated individuals, CoV2^Delta-infected vaccinees, and uninfected vaccinees.

During and shortly after COVID Wave 4 (i.e. that which was caused by CoV2^Delta), saliva from three groups of individuals were collected and used for Ig measurements: those who had not been fully vaccinated and were positive for the CoV2^Delta lineage (Vax^NEGPCR^POS), those who had been fully vaccinated and were positive for the CoV2^Delta lineage (Vax^POSPCR^POS), and those who had been fully vaccinated and were negative for any CoV2 lineage (Vax^POSPCR^NEG). Shown are the (A) IgM^Spike, (B) IgA^Spike and (C) IgG^Spike levels in each individual sample per group. ^X, values that were considered outliers but are nevertheless shown for completeness and are included in all statistical group comparisons. * p≤ 0.05, as determined by unpaired Wilcoxon tests with Benjamini-Hochberg adjustment.

VIII. Despite comparable Spike-specific Ig levels, CoV2^Delta-infected vaccinee saliva was less capable of Spike:ACE2 inhibition, relative to uninfected vaccinees

Since the presence of CoV2-specific Ig does not equate to its having neutralization capacity (71), we next compared the ability of Vax^NEGPCR^POS, Vax^POSPCR^POS and Vax^POSPCR^NEG saliva samples to inhibit Spike:ACE2 interactions. We quantified inhibitory activity using an ACE2 displacement assay (FIG 7A), wherein plate-bound Spike was incubated with the same saliva samples above (i.e., those of FIG 6), followed by washing and addition of a luminescent probe-conjugated, recombinant form of human ACE2. The extent to which luminescence declined relative to non-saliva treated wells was used to derive a percent inhibition value for each individual sample (see Methods for additional details). The results of this analysis are shown in FIG 7B and demonstrate that there were differences between cohorts, the inhibitory activity of VAX^POSPCR^NEG saliva being significantly higher than that of Vax^NEGPCR^POS saliva (FIG 7B). The inhibitory activity of Vax^POSPCR^POS saliva (median=12) was 50% higher than that of Vax^NEGPCR^POS saliva (median=8), but 25% lower than that of Vax^POSPCR^NEG saliva (median=16); as a whole, however, the inhibitory activity of Vax^POSPCR^POS saliva did not significantly differ from that of Vax^NEGPCR^POS saliva, nor did it significantly differ from Vax^POSPCR^NEG saliva (FIG 7B). Within the Vax^NEGPCR^POS cohort, there were no significant correlations between these samples’ inhibitory activity and their IgM^Spike (FIG 7C), IgA^Spike (FIG 7D) or IgG^Spike concentrations (FIG 7E). This was also true of the Vax^POSPCR^POS cohort, as no significant correlations were observed between these samples’ inhibitory activity and their IgM^Spike (FIG 7F), IgA^Spike (FIG 7G) or IgG^Spike concentrations (FIG 7H). Within the Vax^POSPCR^NEG cohort, there were significant correlations between samples’ inhibitory activity and their IgA^Spike concentration (FIG 7J), as well as their IgG^Spike concentration (FIG 7K), but not their IgM^Spike concentration (FIG 7I). When considered alongside the data shown in FIG 6, we conclude COVID vaccination led to increases in saliva IgG^Spike concentrations, the levels being similar between vaccinees who had a breakthrough CoV2^Delta infection (Vax^POSPCR^POS) and vaccinees who did not (Vax^POSPCR^NEG), but that during Wave 4 the antibodies in Vax^POSPCR^POS saliva were limited in their ability to inhibit Spike, the inhibition values being intermediate between Vax^POSPCR^NEG saliva (which had the highest inhibition values) and Vax^NEGPCR^POS controls (which had the lowest inhibition values).

• Download figure
• Open in new tab

FIGURE 7. Inhibition of Spike function by saliva of CoV2^Delta-infected unvaccinated individuals, CoV2^Delta-infected vaccinees, and uninfected vaccinees

(A) Depiction of the probe-conjugated ACE2 displacement assay used to measure saliva samples’ ability to inhibit CoV2 Spike binding to its human receptor, ACE2. The samples in this case were from VAX^NEGPCR^POS, VAX^POSPCR^POS and VAX^POSPCR^NEG individuals (the same samples used for IgM^Spike, IgA^Spike and IgG^Spike measurements in FIG 6 above). (B) The percent inhibition value of each individual sample in each group. Within the (C-E) VAX^NEGPCR^POS group, (F-H) VAX^POSPCR^POS group, and (I-K) VAX^POSPCR^NEG group, the relationship between an individual samples’ inhibition value and cognate (C,F,H) IgM^Spike concentration, (D,G,I) IgM^Spike concentration, and (E,H,J) IgG^Spike concentration. Graph insets indicates the Multiple R-squared value associated with the linear regression model of the respective data set (i.e. the % variation in inhibition that can be explained by the indicated Ig concentration), as well as its p-value (i.e. the significance of the linear model as a whole).